Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: BMS 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: BMS 3Q

Patent expiries demolish revenues, Ph III cancellation pummels earnings

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BMS

3Q Revenues: $3.7 billion (-30%)

3Q Loss: $711 million (earnings were $969 million in 3Q11)

YTD Revenues: $13.4 billion (-15%)

YTD Earnings: $1.0 billion (earnings were $2.9 billion YTD11)

Comments: Revenues were impacted heavily by the U.S. patent expirations for Avapro/Avalide (down 56% to $95 million) and Plavix (down 96% to $64 million). U.S. sales decreased 43% to $2.0 billion in the quarter. International sales decreased 6% to $1.8 billion. Orencia sales were up 32% to $307 million. Yervoy sales were up 48% to $179 million, Sprycel sales grew 25% to $263 million, Onglyza/Kombiglyze sales grew 40% to $178 million, and Baraclude sales grew 11% to $346 million. R&D expenses were $951 million in the quarter, down 2%. The company took a $1.8 billion R&D writedown related to its $2.5 billion acquisition of Inhibitex, after a hepatitis C compound was discontinued in Phase III.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters